News

While FDA’s approval last week of infliximab-dyyb (Inflectra, Celltrion and Hospira), a biosimilar to Remicade (Janssen Biotech) for rheumatoid arthritis, Chron’s disease and other conditions is positive, FDA’s approval pace for biosimilars is too slow, according to a pharmacy benefit manager (PBM).

This year’s Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting 2016, held April 19 to 22 in San Francisco, will feature several sessions of important to managed care professionals. Here are our top 10 recommendations.

Some experts argue that prescription drug monitoring programs can be a game changer when it comes to curbing prescription abuse and misuse. Here are 11 states that stand out for their PDMPs (or lack thereof).

Type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease, according to FDA’s new Drug Safety Communication.

FDA recently approved reslizumab (Cinqair, Teva Pharmaceuticals), an injectable used with other asthma medicines for the maintenance treatment of severe asthma. Here are the top 5 facts to know about Cinqair.

FDA recently approved the first generic version of Nasonex nasal spray (mometasone furoate monohydrate, Apotex Corp).

The sheer volume of diabetes patients has made it a big driver of medication spending. Here are some important formulary considerations.

FDA recently approved antihemophilic factor VIII (recombinant) (Kovaltry, Bayer) for the treatment of hemophilia A in children and adults.

FDA approved ixekizumab (Taltz, Eli Lilly and Co.) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.